ClinicalTrials.gov
ClinicalTrials.gov Menu

Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early MSA (AFF009)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02270489
Recruitment Status : Completed
First Posted : October 21, 2014
Last Update Posted : June 5, 2017
Sponsor:
Collaborators:
University Hospital, Bordeaux
Institut National de la Santé Et de la Recherche Médicale, France
Forschungszentrum Juelich
University Hospital, Toulouse
Information provided by (Responsible Party):
Affiris AG

September 4, 2014
October 21, 2014
June 5, 2017
December 11, 2014
April 18, 2017   (Final data collection date for primary outcome measure)
  • Number of patients who withdraw due to Adverse Events (AEs) [ Time Frame: 12 months ]
  • Occurrence of Adverse Events and Serious Adverse Events [ Time Frame: 12 months ]
    Evaluation of Adverse Events and Serious Adverse Events in regards to autoimmune reactions
  • Physical Examination [ Time Frame: 12 months ]
    New findings or change in pre-existing findings assessed in physical examinations over time (study period)
  • Vital signs [ Time Frame: 12 months ]
    Change in vital signs. The Evaluation includes the changes in blood pressure, heart rate, respiratory rate and Body temperature over time (measured at each visit).
  • Safety related evaluation of MRI results of patients' brain after visit 5 and visit 8 compared to baseline [ Time Frame: 12 months ]
    Safety measures will e.g. include the occurrence of inflammatory reactions (meningoencephalitis), new/changed hemorrhages and lacunar infarcts.
  • Clinical significance/ changes in laboratory parameters over time (study period) [ Time Frame: 12 months ]
    Laboratory assessment includes hematology, biochemistry, coagulation, serology and urinanalysis
  • Body mass [ Time Frame: 12 months ]
    Change of Body mass over time (study period)
  • Neurological Examination [ Time Frame: 12 months ]
    New findings or change in pre-existing findings assessed in neurological examinations over time (study period)
Same as current
Complete list of historical versions of study NCT02270489 on ClinicalTrials.gov Archive Site
  • Immunological activity of AFFITOPE® vaccines PD01A and PD03A. [ Time Frame: 12 months ]
    Titer of vaccination induced antibodies directed towards vaccine components, alpha- and beta synuclein
  • Change in motor symptoms at Visit 5 and Visit 8 compared to baseline [ Time Frame: 12 months ]
    Change in Motor symptoms: UMSARS II (Unified Multiple System Atrophy Rating Scale), CGI (Clinical Global Impression Improvement scale)
  • Change in non-motor symptoms at Visit 5 and Visit 8 compared to baseline [ Time Frame: 12 months ]
    Change in non-motor symptoms: UMSARS I and IV, GDS (Geriatric Depression Scale), COMPASS 31 (Composite Autonomic Symptom Score), MSA-QoL (MSA- Quality of life scale), MOCA (Montreal cognitive assessment), autonomic testing of cardiovascular function
Same as current
Not Provided
Not Provided
 
Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early MSA
A Randomized, Placebo-controlled, Parallel Group, Patient-blind, Phase I Study Assessing the Safety and Exploring the Immunogenicity/Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early Multiple System Atrophy

This is a randomized controlled parallel Group phase I study to investigate the safety and immunological/ therapeutic activity of two new vaccines, AFFITOPE® PD01A and AFFITOPE® PD03A, given to patients with early Multiple System Atrophy (MSA).

In total 30 patients are planned to be enrolled in the study: 12 patients in each treatment arm who will receive either 75µg AFFITOPE® PD01A (with adjuvant) or 75µg AFFITOPE® PD03A (with adjuvant) and 6 patients in the control group who will receive the reference substance (Placebo). Over a study duration of 52 weeks, the study participants will receive 4 injections as basic immunization in a 4-weekly interval and 1 boost immunization 36 weeks after the first injection. Male and female patients aged 30 to 75 years can participate in the trial. 2 study sites in France (Bordeaux and Toulouse) will be involved.

AFF009 is part of the project SYMPATH funded by the European Commission (FP7-HEALTH-2013-INNOVATION-1 project; N° HEALTH-F4-2013-602999).

Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
  • Multiple System Atrophy
  • Neurodegenerative Diseases
  • Biological: AFFITOPE® PD01A + Adjuvant
    s.c. injection
  • Biological: AFFITOPE® PD03A + Adjuvant
    s.c. injection
  • Biological: Adjuvant without active component
    s.c. injection
  • Experimental: AFFITOPE® PD01A + Adjuvant

    4 injections of 75µg AFFITOPE® PD01A/ adjuvanted, once every 4 weeks

    1 boost immunization 36 weeks after first injection

    Intervention: Biological: AFFITOPE® PD01A + Adjuvant
  • Experimental: AFFITOPE® PD03A + Adjuvant

    4 injections of 75µg AFFITOPE® PD03A/ adjuvanted, once every 4 weeks

    1 boost immunization 36 weeks after first injection

    Intervention: Biological: AFFITOPE® PD03A + Adjuvant
  • Placebo Comparator: Adjuvant without active component

    4 injections of Placebo once every 4 weeks

    1 administration 36 weeks after first injection

    Intervention: Biological: Adjuvant without active component
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
Same as current
April 18, 2017
April 18, 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Possible or probably MSA diagnosis (MSA-P or MSA-C) according to Gilman 2008 consensus criteria
  • Onset of MSA symptoms less than 4 years
  • Participants with an anticipated survival of at least 3 years in the opinion of the PI
  • Written informed consent obtained prior to study entry
  • MSA patient > 30 and < 75 years of age at time of study entry
  • Female patients of childbearing potential using a medically accepted contraceptive method
  • Stable medication for MSA symptoms (Levodopa, Dopamine agonists, Midodrine, Fludrocortisone, monoamine oxidase-B and Catechol-O-methyltransferase inhibitors; Antidepressants, Laxatives, NSAIDs or paracetamol as basic medication for pain in the musculoskeletal system)

Exclusion Criteria:

  • Pregnant or lactating women
  • Sexually active women of childbearing potential not using a medically accepted birth control method
  • Patients with dementia (MOCA at Screening < 21)
  • Speech impairment as assessed by a score of ≥ 3 on UMSARS question 1
  • Swallowing impairment as assessed by a score of ≥ 3 on UMSARS question 2
  • Impairment in ambulation as assessed by a score of ≥ 3 on UMSARS question 7
  • History or evidence of any other central nervous system disorder like stroke, angioma and other relevant neurological diseases
  • History of malignancy other than skin cancer during the last 5 years (if considered to be cured, patient might be included)
  • Active or passive vaccination 4 weeks before the first vaccination on Day 0 and during the main study period ending on Day 280. Emergency vaccinations are acceptable
  • Use of any other investigational or non-registered drug or vaccine in addition to the study vaccine during the entire study period
  • Subjects participating or have participated in another interventional clinical trial within 60 days prior to baseline
  • Blood donation within 4 weeks prior to first vaccination.
  • History of autoimmune diseases, severe hypersensitivity reactions and anaphylaxis, allergic bronchial asthma and severe allergic rhinoconjunctivitis
  • Known hypersensitivity or allergic reaction to one of the components of the vaccine
  • A family history of congenital or hereditary immunodeficiency
  • Administration of chronic (defined as more than 14 days) immunosuppressant or other immune-modifying drugs within six months before first vaccination and during the entire study period. For corticosteroids like prednisone or equivalent ≥ 0.05 mg/kg/day. Topical and inhaled steroids are allowed
  • Intake of non steroidal anti-inflammatory drugs (NSAIDs) or paracetamol more than the basic medication for pain in the musculoskeletal system within three days prior to a vaccination with AFFITOPE® PD01A or AFFITOPE® PD03A or Placebo
  • If a patient shows an acute febrile infection (≥ 37.8° Celsius) on the day of vaccination, administration of Investigational Medicinal Product (IMP) should be postponed until resolution of the infection
  • Infection with the human immunodeficiency virus (HIV, a negative test result within 30 days before screening is acceptable), Hepatitis B (HBsAg) or Hepatitis C
  • Significant systemic illness (e.g. chronic renal failure, chronic liver disease, poorly controlled diabetes, poorly controlled congestive heart failure and/or other deficiencies), if considered relevant by the investigator
  • Venous status rendering it impossible to place an i.v. access
  • Contraindications for MRI and lumbar puncture
  • Not able to understand and comply with protocol requirements, instructions, protocol-stated restrictions
  • Unwilling to provide informed consent. Exceptions for patients who are physically not able to provide written informed consent (e.g. legal representative, consent via voce with witness)
Sexes Eligible for Study: All
30 Years to 75 Years   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
France
 
 
NCT02270489
AFFiRiS 009
2014-000567-40 ( EudraCT Number )
Yes
Not Provided
Not Provided
Affiris AG
Affiris AG
  • University Hospital, Bordeaux
  • Institut National de la Santé Et de la Recherche Médicale, France
  • Forschungszentrum Juelich
  • University Hospital, Toulouse
Principal Investigator: Wassilios Meissner, MD, PhD University Hospital Bordeaux (Pellegrin Hospital), Bordeaux 33076, France
Affiris AG
June 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP